In managing patients with hypertension and atrial fibrillation, what beta-blocker is most commonly used for rate control?

In the management of patients with hypertension and atrial fibrillation, metoprolol is the beta-blocker most commonly used for rate control. This preference arises from metoprolol's pharmacological profile, which includes selective action on beta-1 adrenergic receptors primarily found in the heart. This selectivity allows for effective reduction of heart rate and control of ventricular response during atrial fibrillation.

Metoprolol is also well-supported by clinical guidelines specifically for rate control in atrial fibrillation, making it a standard choice for this indication. Additionally, it has a favorable safety profile and is available in both immediate-release and extended-release forms, providing flexibility in dosing and management of different patient needs.

The other beta-blockers mentioned, while they may have some utility in managing hypertension or heart conditions, do not have the same level of endorsement or preference for rate control in atrial fibrillation compared to metoprolol. This makes metoprolol the go-to option in this clinical scenario.